Cochran Collaboration ESA Meta-Analysis Underscores Survival Risk
Executive Summary
A meta-analysis of patient level data from over 10,000 clinical trial patients suggests that use of erythropoiesis-stimulating agents may have an adverse survival impact in the still-approved uses in supportive care for oncology
You may also be interested in...
Amidst ESA Upheaval, FDA Used Mircera Review To Outline Trial “Wish List”
FDA's review of Roche's Mircera BLA became a forum for the agency to set forth a "wish list" for future development of erythropoietin stimulating agents that reflected the seismic upheavals in the conventional understanding of the safety of erythropoietin products
Amidst ESA Upheaval, FDA Used Mircera Review To Outline Trial “Wish List”
FDA's review of Roche's Mircera BLA became a forum for the agency to set forth a "wish list" for future development of erythropoietin stimulating agents that reflected the seismic upheavals in the conventional understanding of the safety of erythropoietin products
As Amgen Drops Some ESA “Overhangs,” New Payment Threat Appears
Amgen could be facing a new threat on the reimbursement front just days after celebrating the removal of several "major overhangs" to its erythropoiesis-stimulating agents during its second quarter earnings call